Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma

Aim Thyroidectomy followed by administration of large activities of 131‐iodine (¹³¹I) is the treatment of choice for differentiated thyroid carcinoma (DTC). The serum thyroglobulin (Tg) measurement during hypothyroidism (offT4‐Tg), just before radioiodine thyroid ablation, has proved to be effective for predicting persistent/recurrent disease. However, the Tg measurement cannot be used as a corresponding value for pre‐ablative offT4‐Tg when recombinant human TSH (rhTSH) is used as stimulus before treatment. The present study was undertaken to evaluate if post‐thyroidectomy Tg values, measured before rhTSH‐stimulated radioiodine ablation is of prognostic value in patients affected by DTC. Methods We enrolled 126 patients with DTC submitted to total thyroidectomy. T4 treatment was started just after surgery to suppress TSH levels and Tg levels (onT4‐Tg) were measured just before rhTSH‐aided thyroid ablation by ¹³¹I (3700 MBq). Neck radioiodine uptake (RAIU) was measured just before ablation and a post‐treatment whole body scan (PT‐WBS) was performed. Results A significant relationship was found between thyroid remnants’ RAIU and onT4‐Tg levels (P < 0·001). The 1·10 ng/ml onT4‐Tg threshold selected by ROC curve analysis identifies patients with positive PT‐WBS with 83·3% sensitivity, 65·7% specificity, 44·5% positive predictive value (PPV) and 93·6% negative predictive value (NPV). The 0·65 ng/ml cut‐off level recognizes metastatic patients with 82·9% sensitivity, 55·2% specificity, 43·3% PPV and 97·8% NPV when compared with 12 months restaging results. Among 63 patients with initially undetectable onT4‐Tg (i.e. ≤ 0·2 ng/ml) none had positive PT‐WBS nor DTC relapse at 12‐month restaging (NPV 100%). Conclusions Based on our data we conclude that pre‐ablative onT4‐Tg is a prognostic marker and should be used instead of pre‐ablative TSH‐stimulated Tg measurement when rhTSH‐aided radioiodine ablation is done.     

Atrial natriuretic peptide and 24 h blood pressure

BACKGROUND: Atrial natriuretic peptide (ANP) is a hormone involved in the cardiovascular modulation of blood pressure and volume homeostasis. OBJECTIVE: To compare ANP levels in normotensives and hypertensives and to correlate ANP levels with ambulatory blood pressure parameters. METHODS: Plasma samples for ANP determination (using a double-antibody radioimmunoassay Kit) were obtained from 33 consecutive subjects (24 hypertensives, nine normotensives) who had rested supine for 30 min. Afterwards, all of the subjects were subjected to 24 h non-invasive blood pressure monitoring. We found no significant difference between the two groups with regard to ANP levels (95.1+/-29 versus 96.9+/-33 pg/ml, in normotensives and hypertensives, respectively). Also, when hypertensive patients were divided according to their family history of hypertension, ANP levels were similar. There was no correlation between the ANP level and the pre-sampling blood pressure or between the ANP level and the following ambulatory blood pressure monitoring parameters: 24 h, diurnal and nocturnal systolic and diastolic blood pressures, systolic and diastolic loads, nocturnal blood pressure reduction and blood pressure variation coefficients. CONCLUSION: Both the pre-sampling blood pressure and ambulatory monitoring results (sustained blood pressures and pressure variations during the 24 h period) do not seem to influence basal ANP levels in patients with hypertension. These data do not account for a role of this peptide in cardiovascular control, in hypertension.     

Variations in radioiodine ablation: decision-making after total thyroidectomy

European Journal of Nuclear Medicine and Molecular Imaging - The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision...     

“Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vide” on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news

European Journal of Nuclear Medicine and Molecular Imaging -     

Determination of cytotoxicity in vivo using 111indium-labeled human tumor cells

Loss of radioactivity from nude mice was determined after inoculation of human tumor cells prelabeled with [111In]indium oxine (111InOx). Elimination of 111In was increased somewhat by treating the mice with diphtheria toxin (DT), which is toxic selectively for human cells compared to mice. Calcium disodium edetate (CaNa2EDTA), a metal chelating agent, facilitated elimination of 111In and increased the difference in the rates of loss of radioactivity from mice bearing viable compared to DT-killed cells.